Santhera Pharmaceuticals Holding AG

LSE:0QN1 Stock Report

Market Cap: CHF 96.8m

Santhera Pharmaceuticals Holding Management

Management criteria checks 2/4

Santhera Pharmaceuticals Holding's CEO is Dario Eklund, appointed in Dec 2019, has a tenure of 4.92 years. total yearly compensation is CHF1.72M, comprised of 30.1% salary and 69.9% bonuses, including company stock and options. directly owns 0.037% of the company’s shares, worth CHF36.00K. The average tenure of the management team and the board of directors is 1.8 years and 4.5 years respectively.

Key information

Dario Eklund

Chief executive officer

CHF 1.7m

Total compensation

CEO salary percentage30.1%
CEO tenure4.9yrs
CEO ownership0.04%
Management average tenure1.8yrs
Board average tenure4.5yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Dario Eklund's remuneration changed compared to Santhera Pharmaceuticals Holding's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

CHF 63m

Mar 31 2024n/an/a

CHF 59m

Dec 31 2023CHF 2mCHF 516k

CHF 55m

Sep 30 2023n/an/a

-CHF 5m

Jun 30 2023n/an/a

-CHF 65m

Mar 31 2023n/an/a

-CHF 68m

Dec 31 2022CHF 2mCHF 505k

-CHF 71m

Sep 30 2022n/an/a

-CHF 68m

Jun 30 2022n/an/a

-CHF 65m

Mar 31 2022n/an/a

-CHF 60m

Dec 31 2021CHF 1mCHF 500k

-CHF 56m

Sep 30 2021n/an/a

-CHF 56m

Jun 30 2021n/an/a

-CHF 56m

Mar 31 2021n/an/a

-CHF 62m

Dec 31 2020CHF 681kCHF 500k

-CHF 68m

Sep 30 2020n/an/a

-CHF 46m

Jun 30 2020n/an/a

-CHF 24m

Mar 31 2020n/an/a

-CHF 21m

Dec 31 2019CHF 2mCHF 42k

-CHF 19m

Compensation vs Market: Dario's total compensation ($USD1.92M) is above average for companies of similar size in the UK market ($USD354.22K).

Compensation vs Earnings: Dario's compensation has been consistent with company performance over the past year.

CEO

Dario Eklund (56 yo)

4.9yrs

Tenure

CHF 1,715,974

Compensation

Mr. Dario Eklund has been Chief Executive Officer at Santhera Pharmaceuticals Holding AG since December 1, 2019. He served as Head of Global Business Operations at Vifor Pharma Ltd. since 2014.He served a...

Leadership Team

NamePositionTenureCompensationOwnership
Thomas Meier
Founder & Chairman7.6yrsCHF 200.00k0.26%
CHF 248.7k
Dario Eklund
Chief Executive Officer4.9yrsCHF 1.72m0.037%
CHF 36.0k
Andrew Smith
Chief Financial Officer4.6yrsno datano data
Oliver Strub
Head of Complianceless than a yearno datano data
Günther Metz
Head Business Developmentno datano data0.0083%
CHF 8.0k
Shabir Hasham
Chief Medical Officerno datano data0.022%
CHF 21.2k
Marc Schrader
Chief Technology Officerless than a yearno datano data
Oliver Kronenberg
Chief Legal Officer & Corporate Secretaryless than a yearno datano data
Neville Kodkani
Head of Global Marketing & Partner Managementno datano datano data
Sarah Holmes-Klotz
Head of People & Culture2.7yrsno datano data
Andreas Missy
Executive Vice President of Corporate Planning & Business Developmentno datano datano data
Geert van Daal
Chief Commercial Officerno datano datano data

1.8yrs

Average Tenure

62yo

Average Age

Experienced Management: 0QN1's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Thomas Meier
Founder & Chairman7.6yrsCHF 200.00k0.26%
CHF 248.7k
Otto Schwarz
Director1.4yrsCHF 143.75kno data
Bradley Meyer
Director1.4yrsCHF 168.75k0.026%
CHF 24.7k
Philipp Gutzwiller
Non Executive Independent Director7.6yrsCHF 145.00k0.11%
CHF 108.0k

4.5yrs

Average Tenure

59yo

Average Age

Experienced Board: 0QN1's board of directors are considered experienced (4.5 years average tenure).